{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-074618","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2026-06-16T20:43:32+00:00","discovered_at":"2026-06-16T20:45:00.289571+00:00","generated_at":"2026-06-16T20:45:52.977058+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Armata shareholders elect directors, approve advisory votes, ratify auditor at 2026 annual meeting","bullets":["All seven director nominees elected for one-year terms: Deborah Birx, Daniel Gilmer, Jules Haimovitz, Odysseas Kostas, Robin Kramer, Joseph Patti, Sarah Schlesinger.","Non-binding advisory vote on named executive officer compensation approved: 28,547,283 for, 27,765 against, 1,257,467 broker non-votes.","One-year frequency for future advisory votes on executive compensation selected: 28,567,809 for one year, 2,400 for two years.","Ratification of Ernst & Young as independent auditor for FY2026 passed: 29,842,514 for, 6,631 against, 0 broker non-votes."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-074618","json":"https://secwatch.observer/filing/0001104659-26-074618.json","markdown":"https://secwatch.observer/filing/0001104659-26-074618.md","text":"https://secwatch.observer/filing/0001104659-26-074618.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465926074618/0001104659-26-074618-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465926074618/tm2618097d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T20:45:52.977058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31f8ee1a726a24122d8a2b61d424c24190147b42","claim":"Armata Pharmaceuticals, Inc. shareholders approved Approval, on a non-binding advisory basis, of a one-year frequency for future advisory votes on named executive officer compensation. at the 2026-06-11 meeting.","evidence_excerpt":"At the Meeting, our shareholders next approved, on a non-binding advisory basis, a one-year frequency for future advisory votes on the Company’s named executive officer compensation. The vote for such approval was 28,567,809 shares for one year, 2,400 shares for two years, 17,113 shares for three years, 4,914 shares abstaining, and 1,257,467 shares of broker non-votes.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926074618/0001104659-26-074618-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"4234a78d1b704ddd4611f010946de0849a293e63","claim":"Armata Pharmaceuticals, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers. at the 2026-06-11 meeting.","evidence_excerpt":"At the Meeting, our shareholders next approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers. The vote for such approval was 28,547,283 shares for, 27,765 shares against, 17,188 shares abstaining, and 1,257,467 shares of broker non-votes.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926074618/0001104659-26-074618-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"47d742a4c639332cb5255075c75374e9246cb3be","claim":"Armata Pharmaceuticals, Inc. shareholders approved Election of seven directors to serve for a one-year term at the 2026-06-11 meeting.","evidence_excerpt":"At the Annual Meeting of Shareholders held on June 11, 2026 (the “Meeting”), the shareholders of Armata Pharmaceuticals, Inc. (the “Company”) elected seven members to our board of directors, each for a one-year term expiring at the annual meeting of shareholders in 2027, as follows: Members Number of Shares Voted For Number of Shares Withheld Broker Non- Votes Deborah L. Birx, M.D. 28,349,266 242,970 1,257,467 Daniel B. Gilmer, Ph.D. 28,543,542 48,694 1,257,467 Jules Haimovitz 28,350,690 241,546 1,257,467 Odysseas D. Kostas, M.D. 28,353,918 238,318 1,257,467 Robin C. Kramer 28,537,772 54,464 1,257,467 Joseph M. Patti, Ph.D. 28,544,094 48,142 1,257,467 Sarah Schlesinger, M.D. 28,354,046 238,190 1,257,467","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926074618/0001104659-26-074618-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"afd91721f9d5a432d3c00acc869f9ced11b422d9","claim":"Armata Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026. at the 2026-06-11 meeting.","evidence_excerpt":"Also at the Meeting, our shareholders ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote for such ratification was 29,842,514 shares for, 6,631 shares against, 558 shares abstaining, and 0 shares of broker non-votes.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926074618/0001104659-26-074618-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}